Suppr超能文献

儿童青霉素过敏测试的健康结果:系统评价。

Health outcomes of penicillin allergy testing in children: a systematic review.

机构信息

Department of Pharmacy, University Hospitals Plymouth NHS Trust, Plymouth, UK.

Department of Pharmacy and Pharmacology, University of Bath, Bath, UK.

出版信息

J Antimicrob Chemother. 2023 Apr 3;78(4):913-922. doi: 10.1093/jac/dkad052.

Abstract

BACKGROUND

Penicillin allergy labels are commonly acquired in childhood and lead to avoidance of first-line penicillin antibiotics. Understanding the health outcomes of penicillin allergy testing (PAT) can strengthen its place in antimicrobial stewardship efforts.

OBJECTIVES

To identify and summarize the health outcomes of PAT in children.

METHODS

Embase, MEDLINE, Web of Science, Cochrane Library, SCOPUS and CINAHL were searched from inception to 11 Oct 2021 (Embase and MEDLINE updated April 2022). Studies that utilized in vivo PAT in children (≤18 years old) and reported outcomes relevant to the study objectives were included.

RESULTS

Thirty-seven studies were included in the review, with a total of 8411 participants. The most commonly reported outcomes were delabelling, subsequent penicillin courses, and tolerability to penicillin courses. Ten studies had patient-reported tolerability to subsequent penicillin use, with a median 93.6% (IQR 90.3%-97.8%) of children tolerating a subsequent course of penicillins. In eight studies, a median 97.3% (IQR 96.4%-99.0%) of children were reported as 'delabelled' after a negative PAT without further definition. Three separate studies verified delabelling by checking electronic or primary care medical records, where 48.0%-68.3% children were delabelled. No studies reported on outcomes relating to disease burden such as antibiotic resistance, mortality, infection rates or cure rates.

CONCLUSIONS

Safety and efficacy of PAT and subsequent penicillin use was the focus of existing literature. Further research is required to determine the long-term impact of delabelling penicillin allergies on disease burden.

摘要

背景

青霉素过敏标签通常在儿童时期获得,并导致避免使用一线青霉素抗生素。了解青霉素过敏测试 (PAT) 的健康结果可以加强其在抗菌药物管理工作中的地位。

目的

确定并总结儿童 PAT 的健康结果。

方法

从建库到 2021 年 10 月 11 日,在 Embase、MEDLINE、Web of Science、Cochrane 图书馆、SCOPUS 和 CINAHL 中进行了检索(Embase 和 MEDLINE 于 2022 年 4 月更新)。纳入了在儿童(≤18 岁)中使用体内 PAT 并报告与研究目标相关的结果的研究。

结果

综述纳入了 37 项研究,共有 8411 名参与者。报告最多的结果是去标签、后续青霉素疗程和对青霉素疗程的耐受性。有 10 项研究报告了患者对后续青霉素使用的耐受性,中位数为 93.6%(IQR 90.3%-97.8%)的儿童耐受后续青霉素疗程。在 8 项研究中,中位数 97.3%(IQR 96.4%-99.0%)的儿童在 PAT 阴性后未经进一步定义即被报告为“去标签”。有三项独立的研究通过检查电子或初级保健医疗记录来验证去标签,其中 48.0%-68.3%的儿童被去标签。没有研究报告与疾病负担相关的结果,如抗生素耐药性、死亡率、感染率或治愈率。

结论

PAT 的安全性和有效性以及随后使用青霉素是现有文献的重点。需要进一步研究确定去标签青霉素过敏对疾病负担的长期影响。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/850e/10068421/b092c28f0257/dkad052f1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验